CN117247461A - 一种融合蛋白igf2-z及在制备抗体药物增敏剂中的应用 - Google Patents
一种融合蛋白igf2-z及在制备抗体药物增敏剂中的应用 Download PDFInfo
- Publication number
- CN117247461A CN117247461A CN202310831728.8A CN202310831728A CN117247461A CN 117247461 A CN117247461 A CN 117247461A CN 202310831728 A CN202310831728 A CN 202310831728A CN 117247461 A CN117247461 A CN 117247461A
- Authority
- CN
- China
- Prior art keywords
- igf2
- fusion protein
- antibody
- cells
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 43
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 42
- 229940125644 antibody drug Drugs 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims description 6
- 102000036639 antigens Human genes 0.000 claims abstract description 17
- 108091007433 antigens Proteins 0.000 claims abstract description 17
- 239000000427 antigen Substances 0.000 claims abstract description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 70
- 210000003712 lysosome Anatomy 0.000 claims description 19
- 230000001868 lysosomic effect Effects 0.000 claims description 19
- 230000015556 catabolic process Effects 0.000 claims description 16
- 238000006731 degradation reaction Methods 0.000 claims description 16
- 230000008685 targeting Effects 0.000 claims description 12
- 238000005516 engineering process Methods 0.000 claims description 9
- 229960005395 cetuximab Drugs 0.000 claims description 7
- 229960004641 rituximab Drugs 0.000 claims description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 10
- 210000000170 cell membrane Anatomy 0.000 abstract description 7
- 230000009471 action Effects 0.000 abstract description 4
- 230000000593 degrading effect Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000009466 transformation Effects 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 35
- 238000001262 western blot Methods 0.000 description 26
- 239000006180 TBST buffer Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 239000006143 cell culture medium Substances 0.000 description 16
- 239000012528 membrane Substances 0.000 description 14
- 238000011534 incubation Methods 0.000 description 13
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 12
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- 239000006166 lysate Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- 101001028831 Homo sapiens Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 9
- 239000002033 PVDF binder Substances 0.000 description 9
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 230000002132 lysosomal effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 6
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 6
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 6
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 6
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 6
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 6
- 239000012083 RIPA buffer Substances 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 229960003677 chloroquine Drugs 0.000 description 6
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000012460 protein solution Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000004153 renaturation Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000001488 sodium phosphate Substances 0.000 description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000001142 circular dichroism spectrum Methods 0.000 description 3
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013861 fat-free Nutrition 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940068935 insulin-like growth factor 2 Drugs 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 2
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000002983 circular dichroism Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000986379 Homo sapiens High mobility group protein HMGI-C Proteins 0.000 description 1
- 101150002416 Igf2 gene Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010026668 snake venom protein C activator Proteins 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种融合蛋白IGF2‑Z及在制备抗体药物增敏剂中的应用,所述融合蛋白IGF2‑Z的氨基酸序列如SEQ ID NO.1所示。本发明融合蛋白IGF2‑Z易于培养和控制、转化操作简单、表达水平高、成本低、周期短。本发明扩展了抗体药物的作用模式,使其具有了降解相关肿瘤抗原的能力,增强了抗体药物的疗效。本发明融合蛋白IGF2‑Z可以用来潜在治疗肿瘤相关疾病,降解潜在的能够与抗体药物识别的肿瘤相关细胞膜上(外)的靶点。
Description
(一)技术领域
本发明属于靶向药物技术领域,涉及基于溶酶体靶向嵌合体(LYTACs)技术的类胰岛素生长因子-2(Insulin-like growth factor 2,IGF-2)融合蛋白质A(Protein A)的Z结构域的重组蛋白及其制备方法与在提高抗体药物性能中的应用。
(二)背景技术
抗体药物,主要靶向细胞膜外(上)的靶标,在恶性肿瘤、自身免疫性疾病、感染性疾病的治疗上发挥着重要作用。然而,抗体药物的研发仍存在不少问题,包括研发技术缺乏创新、研发成本高、临床研究进展缓慢等,也限制了抗体药物的高速发展。
靶向蛋白质降解(Targeted protein degradation,TPD)技术,在高度选择性靶向致病蛋白的同时,通过泛素蛋白酶体途径、靶向溶酶体途径等方式诱导蛋白降解。比如,2022年诺贝尔奖得主Carolyn R.Bertozzi课题组提出的溶酶体靶向嵌合体(lysosome-targeting chimeras LYTACs),是一种将溶酶体靶向受体(LTR)、LYTAC、细胞外靶标蛋白三者相互结合形成三元复合物,进而将细胞外或膜相关蛋白利用溶酶体途径降解的技术。在传统的抗体药物通过与靶标进行非共价结合并阻断其相关功能的基础上,该LYTACs技术将靶标蛋白进一步降解,提升抗体药物的性能。然而,现有的LYTACs是将抗体与特异性糖基进行偶联修饰,合成方式困难,且在人体内可能产生较强免疫原性,这些都限制了LYTACs的大规模发展。
Z结构域(Z domain)是金黄色葡萄球菌表面的蛋白Protein A结构域的突变体,能与商用单抗IgG的Fc段进行高亲和力的结合,可作为一通用的万能抗体连接器。目前已有研究将Z domain与细胞穿透肽(CPP)结合,将胞外的抗体带入到细胞内使抗体发挥作用,但这些方式只能使抗体起到自身免疫的作用,并不能同时降低致病蛋白的表达,从而获得更好的治疗效果。
因此,开发一种能够快速且大量获取、减少免疫原性的LYTACs,对于抗体药物的增效具有重要的意义。
(三)发明内容
本发明目的是提供一种融合蛋白IGF2-Z及其在制备抗体药物增敏剂中的应用,提高抗体药物性能。将溶酶体靶向受体IGF2R的结合配体类胰岛素生长因子-2(Insulin-likegrowth factor 2,IGF-2)与Z domain融合重组,并在大肠杆菌系统中表达,获得融合蛋白IGF2-Z。该融合蛋白完全由基因编码,不需要任何形式的化学修饰,可大规模生产。且通过Zdomain的连接器的作用,IGF2-Z能够与各种抗体药物相结合。利用IGF2-Z作为一种便捷的抗体药物增敏剂,不仅保留抗体药物对癌细胞靶向作用的能力,同时又能将商用抗体药物所靶向的抗原进行降解,降低抗原的表达水平,最终达到了抗体药物增敏的目的,提高抗体药物抗癌效果、减少耐药性的产生。
本发明采用的技术方案是:
本发明提供一种基于溶酶体靶向嵌合体技术的融合蛋白IGF2-Z,所述融合蛋白IGF2-Z的氨基酸序列如SEQ ID NO.1所示,分子量为15.3kDa。
所述融合蛋白IGF2-Z主要有两部分构成,用于识别抗体的Z结构域、起到溶酶体靶向作用的类胰岛素样生长因子2(IGF2)。所述的Z结构域来源于葡萄球菌蛋白A,能够以纳摩尔亲和力与IgG的Fc区域结合,同时此结构域能够与大多数在售的抗体药物(Ab)进行结合,起到万能抗体连接器的作用。所述的融合蛋白IGF2-Z能够借助IGF2靶向哺乳动物细胞膜表面的IGF2R受体,形成复合物(IGF2R/IGF2-Z/Ab/POI,其中POI代表靶标蛋白Protein ofinterest),利用IGF2结合IGF2R后诱导IGF2R转运至溶酶体的性质,将复合物递送至溶酶体,从而对POI进行降解。所述的IGF2R受体为细胞表面跨膜受体又称CI-M6PR受体,是一种溶酶体靶向受体,有10%存在于细胞膜上,可以介导带有甘露糖-6磷酸(M6P)或IGF2修饰的蛋白质转运至溶酶体。而内吞入溶酶体过程中,随着pH的降低,CI-M6PR与结合的蛋白发生解离,CI-M6PR可再度进入循环回到细胞膜上。
本发明还提供一种所述融合蛋白IGF2-Z在制备抗体药物增敏剂中的应用,所述的应用是将融合蛋白IGF2-Z与抗体药物和抗体药物靶向的抗原细胞共同孵育,提高抗体药物对于抗原的降解能力,实现抗体药物靶向的抗原的高效降解。本发明所述的融合蛋白IGF2-Z与商业抗体药物结合后,再与抗体药物所识别的抗原进行结合,促进四级配合物(IGF2R/IGF2-Z/Ab/POI)的形成,使得POI转运至溶酶体被降解,从而增强商业抗体药物的作用。
所述抗原细胞包括人慢性髓原白血病细胞K562、人宫颈癌细胞HeLa、淋巴瘤细胞Raji。所述抗体药物包括西妥昔单抗(Cetuximab,商品名爱必妥(Erbitux))、利妥昔单抗(Rituximab,商品名美罗华)。
本发明融合蛋白IGF2-Z和商用抗体药物与细胞共孵育后,可以靶向细胞膜表面相应抗原并降解,具体的原理为:首先IGF2-Z的Z结构域会与加入的抗体药物的Fc区域以高亲和力的方式连接,随后会在细胞膜上形成IGF2R/IGF2-Z/Ab/POI的四元复合体,最终通过IGF2R-IGF2介导的内化作用将POI转至溶酶体后进行降解。所述细胞为人慢性髓原白血病细胞(K562)。
与现有技术相比,本发明的有益效果主要体现在:
本发明提供一种融合蛋白IGF2-Z,使用的Z结构域是能与人类大多数类型的抗体(比如IgG)的Fc段结合的葡萄球菌蛋白A上的最小化的肽段,其亲和力与葡萄球菌蛋白A几乎相同,但大小只有它的六分之一,便于表达与操作。最终通过IGF2R-IGF2介导的内化作用将抗原(比如POI)转运至溶酶体后进行降解。
本发明通过大肠杆菌的表达系统对融合蛋白IGF2-Z进行表达,易于培养和控制、转化操作简单、表达水平高、成本低、周期短。
本发明相比于靶向降解嵌合体(PROteolysis TArgeting Chimeras,PROTACs)降解胞内蛋白,IGF2-Z是在胞外进行结合,靶向膜上或膜外的抗原蛋白质,并能够将靶向的抗原蛋白通过内化的方式进入细胞后降解。现有抗体药物与靶点之间一般都是动态平衡的结合,本发明扩展了抗体药物的作用模式,使其具有了降解相关肿瘤抗原的能力,增强了抗体药物的疗效。本发明融合蛋白IGF2-Z可以用来潜在治疗肿瘤相关疾病,降解潜在的能够与抗体药物识别的肿瘤相关细胞膜上(外)的靶点。
(四)附图说明
图1为实施例1融合蛋白IGF2-Z提取、纯化过程用考马斯亮蓝(CBB)染色的SDS-PAGE图;A中“+”泳道代表含融合蛋白IGF2-Z质粒的重组菌诱导培养液,“-”泳道代表含融合蛋白IGF2-Z质粒的重组菌未诱导培养液;B中泳道Pel代表重组菌诱导培养液离心后的沉淀,泳道FL代表裂解缓冲液洗脱的穿流液;泳道E1、E2、E3、E4代表洗脱缓冲液洗脱的流出液。
图2为实施例1利用AlphaFold2预测的IGF2-Z蛋白折叠结构。
图3为实施例2中CD光谱曲线。
图4为实施例3激光扫描共聚焦显微镜图像(A)、K562细胞中IGF2-Z的剂量-反应曲线(B)。A中IGF2-ZCy5代表Cy5染料标记的融合蛋白IGF2-Z通道;LysoGreen代表溶酶体绿色荧光探针,Merge代表两种通道重叠。
图5为实施例4流式细胞术分析图。
图6为实施例4中激光扫描共聚焦显微镜图像。
图7为SDS-PAGE凝胶分离分析K562细胞中IGF2-Z与不同抗体(A:IgGCy5;B:CetCy5;C:RituCy5)的时间依赖性摄取(3、8、12、24h)和洗脱(12、24h)。
图8为实施例5中利用蛋白质免疫印迹图(A)验证IGF2-Z和Cet的浓度依赖性实验和与溶酶体抑制剂(50μM CQ或50nM Baf)存在下IGF2-Z和Cet诱导HeLa细胞的EGFR降解的蛋白质免疫印迹图(B)。
图9为IGF2-Z与Cet作用下HeLa细胞的pEGFR和pAKT蛋白质免疫印迹图。
图10为药物治疗后肿瘤组织照片及解剖肿瘤的重量比较。
图11为肿瘤组织中EGFR水平的蛋白质免疫印迹图。
图12为IGF2-Z与Ritu作用下诱导Raji细胞中CD20降解的蛋白质免疫印迹图。
(五)具体实施方式
下面结合具体实施例对本发明进行进一步描述,但本发明的保护范围并不仅限于此:
所述方法如无特别说明均为常规方法。所述原材料如无特别说明均能从公开商业途径获得。以下实施例中的定量试验,均设置三次重复实验,结果取平均值。本发明所述室温是指25-30℃。
细胞培养基:含体积浓度10%胎牛血清(FBS)+青霉素(100μg/mL)+链霉素(100μg/mL)的DMEM完全培养基。
实施例1、融合蛋白蛋白IGF2-Z的构建、表达纯化
1、质粒的构建
委托南京金斯瑞,人工合成含His标签的融合蛋白IGF2-Z,氨基酸序列如SEQ IDNO.2所示,编码基因的核苷酸序列如SEQ ID NO.1所示。同时人工合成Z结构域蛋白(氨基酸序列如SEQ ID NO.2中80-137位所示)。
将含His标签的融合蛋白IGF2-Z的DNA序列片段插入pET-24a(+)载体中,构建质粒pET-24a/IGF2-Z。
将Z结构域蛋白的DNA序列片段插入pET-24a(+)载体中,构建质粒pET-24a/Z。
IGF2-Z氨基酸序列SEQ ID NO.2
MHHHHHHAYRPSETLCGGELVDTLQFVCGDRGFYFSRPASRVSRRSRGIVEEC CFRSCDLALLETYCATPAKSEGGGGSVDNKFNKEQQNAFYEILHLPNLNEEQRNAF IQSLKDDPSQSANLLAEAKKLNDAQAPK。
2、融合蛋白IGF2-Z粗酶的制备
(1)取1-5μL质粒pET-24a/IGF2-Z(50ng/μL)加入到解冻的大肠杆菌BL21(DE3)感受态细胞中,并轻轻混合。将试管放在冰上孵育30min,然后以42℃水浴进行热激处理90秒。后加入到500μL不含抗生素的LB培养基中,在37℃下继续振荡孵育1h。将得到的菌液涂板在含有卡那霉素(50μg/mL)的LB琼脂板上,然后在37℃下进一步孵育16h。在培养皿上形成的单个菌落,挑出送测,单克隆经DNA序列验证正确后用于后续的实验。
(2)将步骤(1)得到的单菌落挑入25mL含卡那霉素(最终浓度为50μg/mL)的LB液体培养基中,在37℃、200rpm摇床下振荡培养9h以上。之后取5mL菌液到150mL的LB培养基中扩大培养2h,当OD600值达到0.6~0.8时,加入IPTG至终浓度为0.5mM诱导细胞,再37℃培养4~5h后,培养液(考马斯亮兰染色,SDS-PAGE凝胶电泳图见图1,其中A“+”为在培养液中添加了IPTG,“-”为在培养液中未添加IPTG),8000rpm离心10分钟,收集菌液沉淀,再用30mL 1xPBS吹打混匀菌体,离心(4℃,8000rpm,10min),去上清,收集到的沉淀放置在-80℃冰箱保存,SDS-PAGE凝胶电泳图见图1中B的泳道Pel。
(3)将步骤(2)收集到的沉淀在15mL裂解缓冲液(20mM磷酸钠、8M尿素、300mM氯化钠、3mM二硫苏糖醇(DTT),溶剂为水,pH 8.0)中重悬,室温静止1小时,然后用细胞超声破碎仪在冰上超声(功率300W、开1s、关3s、10分钟)。将所得到的裂解液在4℃下以12,000rpm离心20min,收集上清。将上清用BCA法测量蛋白含量,后将收集的上清液加入Ni-NTA琼脂糖(Ni-NTA琼脂糖的加入体积根据Ni-NTA的蛋白质负载为50mg/mL计算),在4℃下用旋转摇床上混匀90min,吸附目的蛋白后,装入亲和层析柱,先用裂解缓冲液洗涤,同时流穿液用Bradford法测定蛋白含量(96孔板每孔100μL Bradford试剂加5μL流穿液),收集的流穿液的SDS-PAGE凝胶电泳图见图1中B中泳道FL;然后用洗脱缓冲液洗脱(20mM磷酸钠、8M尿素、300mM氯化钠,溶剂为水,用盐酸调节pH至6.0),洗涤至Bradford不变色,每1mL流出液收集一管,SDS-PAGE凝胶电泳图见图1中B的泳道E1、E2、E3、E4。将全部流出液减压浓缩至干,得到5mg的IGF2-Z粗酶。
3、融合蛋白IGF2-Z纯酶的制备
将步骤2中得到的IGF2-Z的粗酶,用透析法将其复性,取粗酶1.5mg用裂解缓冲液稀释至~0.1mg/mL装入透析袋(截留分子量为10kDa)中,在4℃下使用复性缓冲液(I~IV)透析,每种复性缓冲液1000mL至少透析3小时,然后取截留液转移到下一个复性缓冲液中,最终用1xPBS进行透析,截留液减压浓缩至1mg/mL,得到融合蛋白IGF2-Z纯酶1mg。利用AlphaFold2预测IGF2-Z蛋白折叠结构,见图2所示,结果表明融合蛋白IGF2-Z具有正确折叠。
同样方法,制备Z结构域蛋白纯酶1mg。
复性缓冲液(I~IV)组成:
I:20mM磷酸钠、300mM氯化钠、6M尿素,pH 8.0;
II:20mM磷酸钠、300mM氯化钠、3M尿素,pH 8.0;
III:20mM磷酸钠、300mM氯化钠、1.5M尿素、1mM谷胱甘肽(还原型)GSH、0.2mM谷胱甘肽(氧化型)GSSG,pH 8.0;
IV:20mM磷酸钠、300mM氯化钠、0.5M尿素、1mM GSH、0.2mM GSSG,pH 8.0。
实施例2、融合蛋白IGF2-Z的圆二色性(CD)研究
实施例1步骤3制备的融合蛋白IGF2-Z纯酶用10mM磷酸钾缓冲液(pH值7.2)配制成20μM蛋白溶液,石英样品杯光径0.2cm。在20℃、远紫外CD光谱(260-190nm)下扫描,扫描速度为0.8nm/min,使用JASCO J-815分光偏振仪(JASCO)记录,Peltier系统来控制细胞温度,CD谱图如图3所示,图3表明复性后融合蛋白IGF2-Z的蛋白折叠效果达到预期。
实施例3、细胞K562对Cy5标记融合蛋白IGF2-Z的摄取情况
(1)Cy5标记的融合蛋白IGF2-Z
实验组:实施例1步骤3制备的融合蛋白IGF2-Z用10mM磷酸钾缓冲液(pH 7.2)配制成1mg/mL蛋白溶液,将100μL蛋白溶液加入到400μL Na2CO3缓冲液(500mM,pH=9.0)中,加入6μL浓度1mM的Cy5-NHS(花菁染料CY5标记活性脂)的DMSO溶液,将反应混合物在4℃下震荡孵育过夜后,加入Tris缓冲液(20mM,pH=8.0)中,4℃淬灭30min,获得标记蛋白溶液。将标记蛋白溶液加入透析袋(截留分子量10000,使用前先在ddH2O中煮沸10min并冷却至室温),用1L 1xPBS透析2次去除游离的染料,每次2h,取截留液,即为Cy5标记融合蛋白IGF2-Z,浓度为0.18mg/mL。
对照组:将实验组中蛋白溶液用等体积的Na2CO3缓冲液代替,加入6μLCy5-NHS,将反应混合物在4℃下震荡孵育过夜,用Tris缓冲液淬灭后,作为染料对照样品。
(2)细胞K562对IGF2-Z的摄取检测
人慢性髓原白血病细胞K562接种在细胞培养基中,悬浮、吹打均匀后加入到96孔板,每孔10万细胞,体积200μL,每孔再加入终浓度500nM的Cy5标记的IGF2-Z,置于37℃,5%CO2培养箱中培养24小时,吸去培养基,用PBS(1x)清洗3次,去除残留的标记蛋白,然后重新加入带有50nM溶酶体红色荧光探针LysoTracker Red的细胞培养基中,37℃继续孵育15min后,采用激光扫描共聚焦显微镜(CLSM)进行扫描,结果见图4中A,可以看出IGF2-Z能够有效被K562细胞摄取,并递送至溶酶体当中。
(3)细胞K562对不同浓度IGF2-Z的摄取检测
人慢性髓原白血病细胞K562接种在细胞培养基中悬浮、吹打均匀后加入到96孔板,每孔10万细胞,体积200μL,每孔再加入不同终浓度(0、10、50、100、500、750、1000、2000nM)的Cy5标记的IGF2-Z,置于37℃,5%CO2培养箱中培养24小时,吸去培养基,用PBS(1x)清洗3次,去除残留的标记蛋白,最后加入1mL PBS(1x)混匀,用流式细胞仪(Navios,Beckman)对细胞中的Cy5信号进行检测,根据平均荧光强度Mean值数据绘制剂量-反应曲线,如图4中B所示,结果表明细胞K562对IGF2-Z的摄取常数Kd为287nM。
实施例4、IGF2-Z对细胞K562摄取抗体的影响
(1)Cy5标记抗体
商业购买的IgGs用PBS稀释至1mg/mL抗体溶液,将100μL抗体溶液加入到400μLNa2CO3缓冲液(500mM,pH=9.0)中,加入6μL Cy5-NHS(1mM在DMSO中),将反应混合物在4℃下震荡孵育过夜后,加入Tris缓冲液(20mM,pH=8.0),4℃淬灭30min,获得标记抗体溶液。将透析袋(截留分子量3500)在ddH2O中煮沸10min,将标记抗体溶液加入透析袋,用1L 1xPBS透析2次,每次2h,取截留液,即为Cy5标记IgGs抗体,记作IgGCy5,蛋白浓度为0.17mg/mL。
同样的方法,将IgGs替换为Cetuximab(西妥昔单抗,简称Cet)、Rituximab(利妥昔单抗,简称Ritu)抗体,分别获得Cy5标记Cetuximab抗体,记作CetCy5,蛋白浓度为0.18mg/mL;Cy5标记Rituximab抗体,记作RituCy5,蛋白浓度为0.18mg/mL。
(2)细胞K562共培养
人慢性髓原白血病细胞K562接种在细胞培养基中,悬浮、吹打均匀后,加入到96孔板,每孔10万细胞,体积200μL;将培养孔分为单抗组、单抗+Z组和单抗+IGF2-Z组,其中单抗又分为IgGCy5、CetCy5和RituCy5。
在单抗组的培养孔中,分别加入终浓度100nM的IgGCy5、CetCy5和RituCy5。在单抗+Z组的培养孔中,分别加入终浓度100nM的IgGCy5+终浓度100nM的Z结构域纯蛋白、终浓度100nM的CetCy5+终浓度100nM的Z结构域纯蛋白、终浓度100nM的Ritu Cy5+终浓度100nM的Z结构域纯蛋白。单抗+IGF2-Z组的培养孔中,分别加入终浓度100nM的IgGCy5+终浓度100nM的IGF2-Z纯蛋白、终浓度100nM的CetCy5+终浓度100nM的IGF2-Z纯蛋白、终浓度100nM的RituCy5+终浓度100nM的IGF2-Z纯蛋白。
(3)流式细胞仪检测
步骤(2)孔板置于37℃,5%CO2培养箱中培养24小时,收集细胞,PBS清洗三次,用流式细胞仪对细胞中Cy5信号进行检测。以Tris缓冲液淬灭的Cy5-NHS作为染料对照,结果见图5所示,在K562中同时加入IGF2-Z与IgG孵育24h,IGF2-Z能够有效得将IgG递送到细胞中,柱状图显示3种IgGs(100nM IgGCy5、CetCy5和RituCy5)的Cy5荧光强度。
(4)激光扫描共聚焦显微镜检测
步骤(2)孔板置于37℃,5%CO2培养箱中培养24小时,收集细胞,用PBS(1x)洗2次,然后用Hoechst 33342(100nM)和Lyso-tracker Green(50nM)共染色15min,采用激光扫描共聚焦显微镜进行活细胞共聚焦成像。结果见图6所示,证实了在K562细胞中,在共培养24h后通过IGF2-Z(100nM)摄取了人IgGCy5(100nM),同时IGF2-Z可以将不同的抗体药物递送到细胞内。
(5)凝胶荧光扫描抗体药物摄取情况
步骤(2)孔板置于37℃,5%CO2培养箱中培养24小时,收集细胞,用PBS洗涤三次。然后单抗组转接至新鲜细胞培养基中,37℃,5%CO2孵育24h;单抗+Z组接种至新鲜细胞培养基中,37℃,5%CO2孵育12h和24小时;单抗+IGF2-Z组接种至新鲜细胞培养基中,37℃,5%CO2孵育3、8、12和24h,同时还设置培养基洗脱12、24h,添加500μM氯喹(CQ)孵育24h的对照组。最后,收集细胞,用PBS洗涤,每孔加入100μL含有1mM蛋白酶抑制剂(Beyotime)的RIPA缓冲液,在室温条件下裂解10min,收集裂解液,后用BCA法测定蛋白的浓度,然后将各个裂解液加入到10%的SDS-PAGE凝胶上跑胶分离,最后使用Invitrogen iBright FL1500成像系统成像。上图为荧光成像图,下图为考马斯亮蓝染胶结果图,结果见图7所示。图7表明:不同时间IGF2-Z递送不同抗体药物的差异,且在CQ的存在下递送的抗体药物不会被降解,表面递送的抗体药物是由溶酶体途径进行降解。
实施例5、蛋白质免疫印迹法(Western blotting,WB)分析EGFR降解效果
1、细胞培养
将人宫颈癌细胞HeLa接种在细胞培养基中,悬浮、吹打均匀后接种于12孔板中,37℃,5%CO2培养箱中培养至细胞贴壁占孔板为70~80%(约200000~300000个细胞/孔)。
2、蛋白质免疫印迹法(WB)验证IGF2-Z和Cet的浓度依赖性实验
先将12孔板中的培养液吸出,用1x PBS清洗3次,每孔分别加入不同浓度(0、10、20、50、100、200、1000nM)的IGF2-Z,同时每孔再加入Cet(10nM),再用细胞培养基补足至500μL。在37℃,5%CO2培养箱中培养孵育24h,吸出含有蛋白的培养基,用PBS(1x)洗2次,每孔加入120μL 0.1%Triton X-100,将细胞刮下分别收集到Ep管中,每孔加入100μL含有1mM蛋白酶抑制剂(Beyotime)的RIPA缓冲液,在室温条件下裂解10min,裂解液用BCA法测定蛋白的浓度。接下来,将各个裂解液等量加入到10%的SDS-PAGE凝胶上进行跑胶,然后4℃转膜到聚偏二氟乙烯膜(PVDF膜)上。配制5%的无脂牛奶用TBST缓冲液溶解,将PVDF膜在室温下摇晃封闭膜1.5h。用TBST缓冲液洗涤三次每次10min,后用加入100μL稀释后的EGFR抗体(1:1200稀释度,Cell signaling technology,#4267,用含3%BSA的TBST缓冲液稀释)和5mL稀释后的HRP偶联的GAPDH抗体(1:7500稀释度,用含3%BSA的TBST缓冲液稀释,Proteintech,#HRP-60004),在4℃下孵育过夜。用TBST缓冲液洗涤3次。然后,膜分别加入5mL稀释后的HRP偶联的山羊抗兔IgG(初始浓度0.2mg/mL,Invitrogen,用含3%BSA的TBST缓冲液稀释,1:7500稀释),在室温下孵育1h,用TBST缓冲液洗涤三次,GAPDH作为内参,最后使用Invitrogen iBright FL1500成像系统成像。成像结果采用ImageJ软件对Western印迹(WB)的条带强度进行定量。结果见图8中A所示,结果表明在10nM Cet与20nM IGF2-Z的存在下,细胞当中的EGFR出现降解,并随IGF2-Z的浓度升高降解效果逐渐增加,达到了近85%的EGFR含量的降低。
3、蛋白质免疫印迹法(WB)验证溶酶体抑制剂(50μM CQ或50nM Baf)存在下减弱了IGF2-Z和Cet诱导HeLa细胞的EGFR降解
将HeLa细胞接种在细胞培养基中,悬浮、吹打均匀后接种于12孔板中,37℃,5%CO2培养箱中培养至细胞贴壁占孔板为70~80%(约200000~300000个细胞/孔)。
先将12孔板中的培养液吸出,用1x PBS清洗3次,每孔加入20nM的IGF2-Z,同时每孔再加入Cet(10nM),再用细胞培养基补足至500μL,同时设置空白对照组(Blank),其中以等量的1x PBS代替IGF2-Z和Cet进行孵育。在37℃,5%CO2培养箱中培养孵育24h。
吸出含有蛋白的培养基,用PBS(1x)洗2次,再分别加入500μL含溶酶体抑制剂(50μM CQ或50nM Baf)+细胞培养基,37℃,5%CO2孵育24h,然后吸出含有溶酶体抑制剂的培养基,用PBS(1x)洗2次,每孔加入100μL含有1mM蛋白酶抑制剂(Beyotime)的RIPA缓冲液,在室温条件下裂解10min,裂解液用蛋白质免疫印迹法(WB)检测,结果见图8中B所示,结果表明溶酶体抑制剂的加入会抑制EGFR的降解,表明IGF2-Z起到的降解通路与溶酶体相关。
4、蛋白质免疫印迹法(WB)验证IGF2-Z和Cet诱导HeLa细胞的EGFR与苏氨酸蛋白激酶(Akt)磷酸化水平降低
将HeLa细胞接种在细胞培养基中,悬浮、吹打均匀后接种于12孔板中,37℃,5%CO2培养箱中培养至细胞贴壁占孔板为70~80%(约200000~300000个细胞/孔)。
先将12孔板中的培养液吸出,用1x PBS清洗3次,每孔加入20nM的IGF2-Z,同时每孔再加入Cet(10nM),再用细胞培养基补足至500μL,分别设置Cet、IGF2-Z、Z、Cet+IGF2-Z组,在37℃,5%CO2培养箱中培养孵育24h。
吸出含有蛋白的培养基,用PBS(1x)洗2次,并进一步用EGF(100ng/mL)在37℃下处理20min。孵育后,每孔加入100μL含有1mM蛋白酶抑制剂(Beyotime)的RIPA缓冲液,在室温条件下裂解10min,裂解液用蛋白质免疫印迹法(WB)检测EGFR、AKT磷酸化水平。接下来,将各个裂解液等量加入到10%的SDS-PAGE凝胶上进行跑胶,然后4℃转膜到聚偏二氟乙烯膜(PVDF膜)上。配制5%的无脂牛奶用TBST缓冲液溶解,将PVDF膜在室温下摇晃封闭膜1.5h。用TBST缓冲液洗涤三次每次10min,后用加入5mL稀释后的Anit-phospho-EGFR(Y1068)抗体(1:2000稀释度,Cell signaling technology,#2234,用含3%BSA的TBST缓冲液稀释)、5mL稀释后的Anti-phospho-Akt(S473)(1:1000稀释度,用含3%BSA的TBST缓冲液稀释,Huabio,#ET1607-73)、5mL稀释后的HRP偶联的GAPDH(1:7500稀释度,用含3%BSA的TBST缓冲液稀释,BBI),在4℃下孵育过夜。用TBST缓冲液洗涤3次。然后,膜分别加入5mL稀释后的HRP偶联的山羊抗兔IgG(初始浓度0.2mg/mL,Invitrogen,用含3%BSA的TBST缓冲液稀释,1:7500稀释),在室温下孵育1h,用TBST缓冲液洗涤三次,GAPDH作为内参,最后使用Invitrogen iBright FL1500成像系统成像。成像结果采用ImageJ软件对Western印迹(WB)的条带强度进行定量。结果见图9所示,结果表明IGF2-Z和Cet的存在下会抑制磷酸化的EGFR、磷酸化Akt的水平,也说明IGF2-Z和Cet能够降低细胞中的EGFR水平,使得下游磷酸化水平也得以降低。
实施例6、IGF2-Z体内降解肿瘤
实验小鼠:4周龄雌性BABL/c裸鼠(~10g)购自上海SLAC实验动物有限公司(中国上海,ICP 05033115)。所有的动物均在温度(23±2℃)、湿度(55±5%)和光照(12h光照/暗循环)的控制条件下饲养。购买来的小鼠正常培养1周后,将100μL悬浮的HeLa细胞(5×106细胞)注射到右背侧皮下荷瘤。
分组:当肿瘤体积达到~100mm3,小鼠随机分为5组(3小鼠/组),分别设置PBS组、Cet对照组、Cet+IGF2-Z治疗组。
治疗:PBS组注射PBS,注射量与加药组加药量相同;Cet对照组注射西妥昔单抗,注射量5mg/kg的蛋白质;Cet+IGF2-Z治疗组注射西妥昔单抗和IGF2-Z纯蛋白,Cet注射量为5mg/kg,IGF2-Z注射量为5mg/kg。各组每两天注射一次,共7次。
治疗结束后,最终处死所有小鼠并收集肿瘤以获得确切的体重,结果见图10所示。图10表明IGF2-Z和Cet的存在会对肿瘤有抑制效果,肿瘤的重量减小。
从不同处理组获得的肿瘤组织用PBS洗涤,并在含有1mM蛋白酶抑制剂(Beyotime)的RIPA缓冲液中研磨。样品在冰上保存1小时。以12000rpm,4℃离心10min,去除组织或细胞碎片。对等量的上清液进行Western blot(WB)分析,结果见图11所示,结果表明IGF2-Z和Cet的存在下会对肿瘤有抑制效果,对肿瘤的EGFR有降解作用。
实施例7、蛋白质免疫印迹法(Western blotting,WB)分析CD20降解效果
1、细胞培养
Raji细胞接种在细胞培养基中,悬浮、吹打均匀后接种于12孔板中,37℃,5%CO2培养箱中培养至细胞贴壁占孔板为70~80%(约200000~300000个细胞/孔)。
2、蛋白质免疫印迹法(WB)验证IGF2-Z和Ritu对CD20的降解效果
每孔分别加入100nM IGF2-Z,10nM Ritu及100nM IGF2-Z+10nM Ritu,以没有任何试剂的加入做为blank对照组。在37℃,5%CO2培养箱中培养孵育48h,收集细胞,用PBS(1x)洗2次,每个样品中加入100μL含有1mM蛋白酶抑制剂(Beyotime)的RIPA缓冲液,在室温条件下裂解10min,裂解液用BCA法测定蛋白的浓度。接下来,将各个裂解液等量加入到15%的SDS-PAGE凝胶上进行跑胶,然后4℃转膜到聚偏二氟乙烯膜(PVDF膜)上。配制5%的无脂牛奶用TBST缓冲液溶解,将PVDF膜在室温下摇晃封闭膜1.5h。用TBST缓冲液洗涤三次每次10min,后用加入5mL CD20抗体(1:2000稀释度,Huabio,#ET1065-33,用含3%BSA的TBST缓冲液稀释)和5mL稀释后的HRP偶联的GAPDH抗体(1:7500稀释度,用含3%BSA的TBST缓冲液稀释,Proteintech,#HRP-60004),在4℃下孵育过夜。用TBST缓冲液洗涤3次。然后,膜分别加入5mL稀释后的HRP偶联的山羊抗兔IgG(初始浓度0.2mg/mL,Invitrogen,用含3%BSA的TBST缓冲液稀释,1:7500稀释),在室温下孵育1h,用TBST缓冲液洗涤三次,GAPDH作为内参,最后使用Invitrogen iBright FL1500成像系统成像。成像结果采用ImageJ软件对Western印迹(WB)的条带强度进行定量。结果见图12中所示,结果表明仅在10nM Ritu与20nM IGF2-Z的存在下,细胞中的CD20达到了近70%的降低,尤其也表明了IGF2-Z的加入提高了CD20抗体药物Rituximab的药效,为后续开发提供了证明。
Claims (5)
1.一种基于溶酶体靶向嵌合体技术的融合蛋白IGF2-Z,其特征在于,所述融合蛋白IGF2-Z的氨基酸序列如SEQ ID NO.1所示。
2.一种权利要求1所述融合蛋白IGF2-Z在制备抗体药物增敏剂中的应用。
3.如权利要求2所述的应用,其特征在于,所述的应用是将融合蛋白IGF2-Z与抗体药物和抗体药物靶向的抗原细胞共同孵育,提高抗体药物对于抗原的降解能力,实现抗体药物靶向的抗原的高效降解。
4.如权利要求3所述的应用,其特征在于,所述抗原细胞包括人慢性髓原白血病细胞K562、人宫颈癌细胞HeLa、淋巴瘤细胞Raji。
5.如权利要求3所述的应用,其特征在于,所述抗体药物包括西妥昔单抗、利妥昔单抗。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310831728.8A CN117247461A (zh) | 2023-07-07 | 2023-07-07 | 一种融合蛋白igf2-z及在制备抗体药物增敏剂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310831728.8A CN117247461A (zh) | 2023-07-07 | 2023-07-07 | 一种融合蛋白igf2-z及在制备抗体药物增敏剂中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117247461A true CN117247461A (zh) | 2023-12-19 |
Family
ID=89130238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310831728.8A Pending CN117247461A (zh) | 2023-07-07 | 2023-07-07 | 一种融合蛋白igf2-z及在制备抗体药物增敏剂中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117247461A (zh) |
-
2023
- 2023-07-07 CN CN202310831728.8A patent/CN117247461A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW202023613A (zh) | 一種抗Claudin18_2抗體及其應用 | |
CN107814845B (zh) | 新的抗pd-1纳米抗体及其应用 | |
ES2367675T3 (es) | Anticuerpo anti-epcam y usos del mismo. | |
CN112457404B (zh) | 一种抗人egfr的纳米抗体和应用 | |
US20120195895A1 (en) | Fusion Protein of an Anti-CD20 Antibody Fab Fragment and Lidamycin, a Method for Preparing the Same, and the Use Thereof | |
CN110128513B (zh) | 一种对eb病毒lmp2蛋白c端胞膜外区具有结合亲和力的多肽及其应用 | |
CN115093477A (zh) | 一种抗新型冠状病毒核蛋白n端区的单克隆抗体及其应用 | |
US20210100887A1 (en) | Recombinant fusion protein and immunogenic composition | |
CN101143902B (zh) | 抗HER2单链抗体-力达霉素强化融合蛋白HER2(Fv-LDM) | |
EP3138907B1 (en) | Antibody gene expression-secretion system | |
CN117247461A (zh) | 一种融合蛋白igf2-z及在制备抗体药物增敏剂中的应用 | |
CN101015689A (zh) | 基于血管紧张素ⅱ的肿瘤多肽疫苗 | |
CN105820219A (zh) | 对hpv18 e7蛋白具有结合亲和力的多肽及其应用 | |
CN112646035B (zh) | Egfr的亲和力成熟结合蛋白及应用 | |
CN111848805A (zh) | 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体 | |
CN102516392A (zh) | 一种癌靶向超抗原融合蛋白及制备方法及用途 | |
CN109593131B (zh) | 一种抗14-3-3η蛋白单克隆抗体及其用途 | |
ES2274649T3 (es) | Influencia sobre la angiogenesis mediante cd66a. | |
CN107041950A (zh) | 一种多房棘球蚴多表位疫苗ltb‑ae的设计、制备方法和应用 | |
CN106075416A (zh) | 一种新型多房棘球蚴亚单位疫苗的设计、制备方法和应用 | |
Shan et al. | scFv-mediated delivery of truncated BID suppresses HER2-positive osteosarcoma growth and metastasis | |
CN108864283B (zh) | 一种脑部靶向转铁蛋白受体的单链抗体及应用 | |
CN111944056A (zh) | 凋亡蛋白融合型抗her-2单链抗体及其制备方法和应用 | |
CN104611296A (zh) | 一株分泌抗重组日本血吸虫烯醇化酶特异性单克隆抗体的杂交瘤细胞及其制备方法与应用 | |
CN110642928A (zh) | 一种对eb病毒lmp1c端蛋白特异性结合的多肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |